joined Neuren on October 1, 2006 and released on February 17, 2018;
see facebook here:
https://www.facebook.com/jamesbonnar
released by Neuren to enter Nyrada that has been set up by Noxo in recent months to study neurodegenative diseases like NNZ-2591.
this is his new preamble in Nyrada:
http://www.nyrada.com/site/About-Nyrada-Inc/management
is a chemist who is enabled to take the drug from preclinical to phase 2 with a toxicological study. in Neuren evidently for Rett and FX it has nothing more to do, but for NNZ-2591 yes; I therefore assume that either NNZ-2591 will be advanced by a staff other than Neuren unless Bonnar has decided to make a career elsewhere.
a few days are left and we will know many more things.
joined Neuren on October 1, 2006 and released on February 17,...
Add to My Watchlist
What is My Watchlist?
